Studies on the rate of reduction of hepatic microsomal cytochrome P-450 by reduced nicotinamide adenine dinucleotide phosphate: effect of drug substrates.
D000632:Aminopyrine / Q000494:pharmacology; D000814:Aniline Compounds / Q000494:pharmacology; D000818:Animals; D002248:Carbon Monoxide / Q000494:pharmacology; D003580:Cytochromes / Q000378:metabolism*; D005021:Ethylamines / Q000494:pharmacology; D005260:Female; D006591:Hexobarbital / Q000494:pharmacology; D007099:Imipramine / Q000494:pharmacology; D066298:In Vitro Techniques; D007700:Kinetics; D008099:Liver / Q000378:metabolism*; D008297:Male; D008748:Methylcholanthrene / Q000494:pharmacology; D008861:Microsomes / Q000378:metabolism*; D009019:Morphinans / Q000494:pharmacology; D009249:NADP / Q000494:pharmacology*; D009536:Niacinamide / Q000494:pharmacology; D010084:Oxidation-Reduction; D011335:Proadifen / Q000494:pharmacology; D051381:Rats; D012737:Sex Factors; D013053:Spectrophotometry; D013997:Time Factors; D014631:Valerates / Q000494:pharmacology
D000814:Aniline Compounds; D003580:Cytochromes; D005021:Ethylamines; D009019:Morphinans; D014631:Valerates; D000632:Aminopyrine; D009536:Niacinamide; D009249:NADP; D008748:Methylcholanthrene; D002248:Carbon Monoxide; D011335:Proadifen; D006591:Hexobarbital; D007099:Imipramine